Expression and significance of DOK2 in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Docking protein 2 (DOK2) expression is reduced in lung adenocarcinoma and gastric cancer.
• DOK2 functions as a tumor suppressor in various solid tumors.
• The role of DOK2 in colorectal cancer prognosis requires further investigation.

Purpose of the Study:

• To determine the clinical significance of DOK2 expression in colorectal cancer.
• To evaluate the correlation between DOK2 levels and patient prognosis.
• To assess DOK2 as a potential prognostic biomarker in colorectal cancer.

Main Methods:

• Analysis of DOK2 protein expression in 102 colorectal cancer patient samples using immunohistochemistry.
• Correlation of DOK2 expression with clinicopathological parameters via univariate and multivariate analyses.
• Assessment of survival outcomes in relation to DOK2 expression levels.

Main Results:

• DOK2 expression was present in normal colorectal mucosa but absent in 33.3% of tumor specimens.
• Colorectal cancer patients with negative DOK2 expression (DOK2(-)) showed a higher likelihood of recurrence.
• DOK2(-) patients had a significantly poorer five-year overall survival rate (59.1%) compared to DOK2(+) patients (76.4%).

Conclusions:

• DOK2 expression levels are significantly associated with prognosis in colorectal cancer patients.
• Reduced DOK2 expression is a potential indicator of poor prognosis in colorectal cancer.
• DOK2 may serve as a valuable prognostic marker for patients undergoing curative resection for colorectal cancer.